• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer

MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Special Reports
  • Technologies
    • Artificial Intelligence (AI)
    • Cardiovascular
    • Orthopedics
    • Neurological
    • Diabetes
    • Surgical Robotics
  • Business & Finance
    • Wall Street Beat
    • Earnings Reports
    • Funding Roundup
    • Mergers & Acquisitions
    • Initial Public Offering (IPO)
    • Legal News
    • Personnel Moves
    • Medtech 100 Stock Index
  • Regulatory
    • Food & Drug Administration (FDA)
    • Recalls
    • 510(k)
    • Pre-Market Approval (PMA)
    • MDSAP
    • Clinical Trials
  • Resources
    • About MassDevice
    • Leadership in Medtech
    • Manufacturers & Suppliers Search
    • MedTech100 Index
    • Videos
    • Webinars
    • Whitepapers
    • Voices
    • In-Depth Coverage
    • Latest News
  • Attend DeviceTalks
    • Events
      • DeviceTalks Minnesota – May 4
      • DeviceTalks Boston – May 27–28
      • DeviceTalks West
      • DeviceTalks Tuesdays
    • DeviceTalks Podcast Network
      • DeviceTalks Weekly
      • AbbottTalks
      • Boston ScientificTalks
      • DeviceTalks AI
      • IntuitiveTalks
      • MedtechWOMEN Talks
      • MedtronicTalks
      • Neuro Innovation Talks
      • Ortho Innovation Talks
      • Structural Heart Talks
      • StrykerTalks
  • Advertise
  • Subscribe
Home » Johnson & Johnson will appeal ‘Texas two-step’ decision to Supreme Court

Johnson & Johnson will appeal ‘Texas two-step’ decision to Supreme Court

March 23, 2023 By Chris Newmarker

Picture of SCOTUS Supreme Court building in Washington where the court could decide on the Texas two-step strategy at J&J Johnson & Johnson.
The front of U.S. Supreme Court in Washington, D.C. [Adobe stock photo]
A federal appeals court will not reconsider its rejection of J&J’s complex legal maneuver to shield itself from talc-related liability.

The U.S. Court of Appeals for the Third Circuit’s decision on J&J’s “Texas two-step” could set the stage for a U.S. Supreme Court ruling in a case that’s drawn a great deal of attention in corporate legal circles. The case affects other companies, such as 3M, that are trying their own complex legal maneuvers in bankruptcy courts in order to limit liability.

In a company statement after the Third Circuit decision yesterday, Johnson & Johnson said it would immediately move for a stay on the opinion while it seeks Supreme Court review.

J&J faces a host of lawsuits from people who claim J&J’s talc-based baby powder caused them to develop cancer.

A New Yorker expose last year detailed how the Texas two-step worked for J&J. Johnson & Johnson created a new LLC called LTL Management and then moved the talc liability over to LTL. The new LLC then filed for Chapter 11 bankruptcy protection. Calling the bankruptcy a “shell game,” plaintiffs in the talc lawsuits appealed. (J&J also plans to spin off its consumer business into a new company called Kenvue in 2023.)

Thomas Ambro, the circuit judge, wrote in the ruling filed Jan. 30 that “only those facing financial distress can call on bankruptcy’s tools to do so.” Now, the full Third Circuit has declined to reconsider.

Said Johnson & Johnson: “Today’s ruling ignores the facts established during the Bankruptcy Court’s trial regarding the appropriateness of LTL Management’s (LTL) formation and filing, as well as the company’s intention to efficiently resolve the cosmetic talc litigation for the benefit of all parties, including current and future claimants.”

The company argues that its Johnson’s Baby Powder is safe, does not contain asbestos, and does not cause cancer.

Filed Under: Business/Financial News, Featured, Legal News, News Well, Product Liability

More recent news

  • Zimmer Biomet, Think Surgical extend exclusive distribution agreement
  • Cambridge Heartwear inks £184M deal to supply NHS with portable ECG monitors
  • J&J, Smith+Nephew plans for ortho megamerger reportedly fall through
  • California and Massachusetts still reign as top US medtech headquarters locations
  • Teleflex wins Breakthrough Device designation for Freesolve resorbable scaffold

About Chris Newmarker

Chris Newmarker is the executive editor of WTWH Media life science's news websites and publications including MassDevice, Medical Design & Outsourcing and more. A professional journalist of 18 years, he is a veteran of UBM (now Informa) and The Associated Press whose career has taken him from Ohio to Virginia, New Jersey and, most recently, Minnesota. He’s covered a wide variety of subjects, but his focus over the past decade has been business and technology. He holds bachelor’s degrees in journalism and political science from Ohio State University. Connect with him on LinkedIn or email at [email protected].

Primary Sidebar

“md
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest med device regulatory, business and technology news.

DeviceTalks Weekly

See More >
MDO ad
MDO ad

Footer

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion
Drug Discovery & Development
Pharmaceutical Processing World
MedTech 100 Index
R&D World
Medical Design Sourcing

DeviceTalks Webinars, Podcasts, & Discussions

Attend our Monthly Webinars
Listen to our Weekly Podcasts
Join our DeviceTalks Tuesdays Discussion

MASSDEVICE

Subscribe to MassDevice E-Newsletter
Advertise with us
About
Contact us

Copyright © 2026 · Arrowfly LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of Arrowfly.

Privacy Policy